Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Current and Emerging Immunotherapies in SCLC: Promise and Challenges
Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based
This continuing medical education (CME) activity is designed to inform physicians about the emerging role of immunotherapy in the treatment of small cell lung cancer (SCLC).
Benefits of Participating
- Learn expert perspectives on the best strategies for combining immunotherapy with chemotherapy for the treatment of SCLC patients
- Integrate the results of the latest clinical studies into your practice decisions
- Explain safety considerations of chemo-immunotherapy combination therapy in SCLC
- Outline the latest strategies for the use of immunotherapy in patients with previously treated SCLC
Instructions for This Activity and Receiving Credit
Upon successful completion of this educational activity, you should be better prepared to:
- Describe the benefit of adding immunotherapy to first-line chemotherapy for SCLC
- Discuss the safety of first-line chemo-immunotherapy combination therapy in SCLC
- Analyze the efficacy of immunotherapy in patients with previously treated SCLC
Faculty, Staff, and Planners’ Disclosures
Associate Professor of Medicine
Director, Thoracic Oncology
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Disclosures: Grant/Research Support: Alkermes, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Clovis Oncology, Corvus Pharmaceuticals, Debiopharm, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics; Consultant: Apollomics, AstraZeneca, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech, Guardant Health, Heron Therapeutics, Ignyta, Inivata, Janssen, Lilly, LOXO Oncology, Merck, MSD, Pfizer, PharmaMar, Regeneron, Roche, Taiho, Takeda/Ariad, Tempus.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
This activity is funded by PER®.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.